← All trials
NCT07181486
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2025
- Primary completion
- Feb 28, 2027
- Completion date
- Oct 31, 2027
- First posted
- Sep 18, 2025
- Last posted
- Sep 18, 2025
- Enrollment
- 12
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoSponsor investigator
- Duke UniversityCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of California, San FranciscoOfficial
- Osel, Inc.Collaborator
- DF/Net ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.